Pain management in laboratory animals is generally accomplished by using
opioids and
NSAIDs. However,
opioid use is hindered by
controlled substance requirements and a relatively short duration of action. In this study, we compared the
analgesic efficacy of
firocoxib (a cyclooxygenase-2-selective NSAID) with that of
buprenorphine in the mouse model of plantar incisional
pain by objective measurement of
mechanical allodynia and
thermal hyperalgesia using von Frey and Hargreaves equipment, respectively. Our experimental design included 5 treatment groups:
firocoxib at 10 mg/kg IP every 24 h (F10 group);
firocoxib at 20 mg/kg IP every 24 h (F20);
buprenorphine at 0.2 mg/kg SC every 8 h; intraperitoneal
normal saline every 24 h; and
sham group (
anesthesia, no incision) treated with
firocoxib at 20 mg/kg IP every 24 h (sham+F20). All mice underwent nociceptive assays at 24 h before and 4, 24, 48, and 72 h after surgery.
Buprenorphine alleviated
allodynia at all time points after incision. The F10 treatment alleviated
allodynia at 4, 24, and 48 h, whereas F20 alleviated
allodynia at 24, 48, and 72 h. None of the treatments alleviated
thermal hyperalgesia at 4h. Except for F10 and
buprenorphine at 24 h, all treatments alleviated
thermal hyperalgesia at 24, 48, and 72 h. No significant differences were noted between the 2 doses of
firocoxib and
buprenorphine regarding
mechanical allodynia and
thermal hyperalgesia at all time points. In conclusion, the
analgesic efficacy of
firocoxib is comparable to that of
buprenorphine in this mouse
pain model.